Noxopharm Secures Flexible $5m At-the-Market Equity Facility with Acuity Capital

Noxopharm Ltd. ( (AU:NOX) ) has shared an update.

Noxopharm Limited has entered into an At-the-Market Subscription Agreement with Acuity Capital, securing access to up to $5 million in standby equity capital over a five-year period to July 2031. The facility gives the company full discretion over whether to draw on the funding, the number of shares issued, pricing floors and timing, and can be terminated at any time without penalty, while placing no restrictions on alternative capital-raising avenues.

As security for the arrangement, Noxopharm will place 15 million fully paid ordinary shares from its existing capacity with Acuity Capital at nil cash consideration, with the option to buy back and cancel these shares at no cost upon early termination or maturity, subject to shareholder approval. The flexible structure is designed to provide additional balance sheet support and financial agility as the company advances its Sofra and Chroma platform-based drug development programs in the competitive cancer and autoimmune therapeutics space.

The most recent analyst rating on (AU:NOX) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Noxopharm Ltd. stock, see the AU:NOX Stock Forecast page.

More about Noxopharm Ltd.

Noxopharm Limited is a clinical-stage Australian biotech company focused on discovering and developing novel treatments for cancer and inflammatory and autoimmune diseases. Its pipeline is built on two proprietary technology platforms, Sofra, which targets inflammation, autoimmunity, mRNA drug enhancement and oncology, and Chroma, which is focused on oncology, positioning the company in large and fast-growing immunology and immuno-oncology markets.

Average Trading Volume: 172,577

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$20.46M

Learn more about NOX stock on TipRanks’ Stock Analysis page.